Screener
Regeneron Pharmaceuticals REGN Contract Liabilities, Non-Current
Contract Liabilities, Non-Current at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The source filing: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 6:52 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000872589-26-000025
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total current liabilities | 5,530.6 | 4,368.4 |
| Long-term debt | 1,986.6 | 1,985.9 |
| Finance lease liabilities | — | 720.0 |
| Deferred revenue | 220.4 | 208.7 |
| Other noncurrent liabilities | 2,281.6 | 2,018.8 |
| Total liabilities | 10,019.2 | 9,301.8 |
| Stockholders' equity: | ||
| Preferred Stock, par value $.01 per share; 30.0 shares authorized; shares issued and outstanding - none | — | — |
Item 1. Financial Statements (unaudited)
FAQ
- What is Regeneron Pharmaceuticals's contract liabilities, non-current?
- Regeneron Pharmaceuticals (REGN) reported contract liabilities, non-current of $220.4M in Q2 2026.
- How has Regeneron Pharmaceuticals's contract liabilities, non-current changed year-over-year?
- Regeneron Pharmaceuticals's contract liabilities, non-current increased by 6.8% year-over-year, from $206.3M to $220.4M.
- What is the long-term trend for Regeneron Pharmaceuticals's contract liabilities, non-current?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's contract liabilities, non-current has grown at a 29.3% compound annual growth rate (CAGR), from $57.8M to $208.7M.
Ask your AI about Regeneron Pharmaceuticals's contract liabilities, non-current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude